---
title: "PT-141 (Bremelanotide)"
slug: "pt-141"
type: "compound"
category: "Sexual Wellness"
url: "https://peptidesciencethailand.com/compounds/pt-141"
description: "FDA-approved melanocortin agonist (Bremelanotide) for hypoactive sexual desire. Central nervous system mechanism, clinical trial data, and usage guidance."
---
# PT-141 (Bremelanotide)

*Melanocortin Receptor Agonist, Central Nervous System Approach to Sexual Function*

**Category:** Sexual Wellness  
**Format:** Lyophilized Vial  
**Amount:** 10mg  
**Purity:** >99.1% (HPLC)

## Overview

PT-141, also known as Bremelanotide, is a cyclic heptapeptide derived from the alpha-melanocyte-stimulating hormone (α-MSH) analogue Melanotan II. While Melanotan II was originally developed for tanning applications at the University of Arizona, researchers observed significant effects on sexual function during early trials, a serendipitous discovery that led to the development of PT-141 as a targeted compound for sexual dysfunction. In 2019, PT-141 received FDA approval under the brand name Vyleesi for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women, making it the first FDA-approved treatment for this condition that works through central nervous system mechanisms.

PT-141's mechanism of action is fundamentally different from phosphodiesterase type 5 (PDE5) inhibitors like sildenafil (Viagra) or tadalafil (Cialis), which act peripherally on vascular smooth muscle to enhance blood flow. Instead, PT-141 acts centrally in the brain by selectively activating melanocortin-3 (MC3R) and melanocortin-4 (MC4R) receptors in the hypothalamus and limbic system, brain regions that govern sexual desire, arousal, and motivated behavior. This central mechanism means PT-141 influences the psychological and neurological components of sexual function rather than simply enhancing vascular mechanics.

The melanocortin system plays a fundamental role in the neurobiology of sexual behavior. MC4R activation in the hypothalamus triggers downstream signaling cascades involving oxytocin and dopamine release, which mediate desire, arousal, and reward pathways. Research published in the Journal of Sexual Medicine demonstrated that PT-141 activates these pathways independently of the vascular system, making it effective in cases where PDE5 inhibitors fail, particularly in individuals whose sexual dysfunction has neurological, psychological, or hormonal rather than purely vascular origins.

Clinical trials leading to FDA approval enrolled over 1,200 premenopausal women with HSDD and demonstrated statistically significant improvements in sexual desire and reductions in distress associated with low desire. The RECONNECT trials (Phase III) showed that women receiving PT-141 reported meaningful increases in desire, arousal, and overall sexual satisfaction compared to placebo.

In male sexual dysfunction research, PT-141 has shown efficacy in cases unresponsive to PDE5 inhibitors. A double-blind, placebo-controlled study published in the journal Urology demonstrated that PT-141 produced erections in men with erectile dysfunction who had not responded to sildenafil, confirming its distinct mechanism of action. This finding is significant because PDE5-inhibitor non-response affects an estimated 30-40% of men with erectile dysfunction.

PT-141 is typically administered on an as-needed basis, 45 minutes before anticipated sexual activity. Its onset of action aligns with central nervous system processing rather than peripheral vascular response, and its effects are reported to be more holistic, enhancing desire and arousal alongside physical response rather than producing physical response in the absence of desire.

specialist consultation is essential for PT-141 because its cardiovascular profile requires careful assessment. PT-141 can cause transient increases in blood pressure and decreases in heart rate, and has been associated with nausea in some individuals. Cardiovascular screening and blood pressure monitoring are necessary before and during use.

## Mechanism of Action

### Step 1: MC3R/MC4R Receptor Activation

PT-141 selectively activates melanocortin-3 and melanocortin-4 receptors in the hypothalamus and limbic system, brain regions governing sexual desire, arousal, and motivated behavior.

### Step 2: Hypothalamic Signaling Cascade

MC4R activation in the paraventricular nucleus triggers downstream neuronal signaling cascades that initiate sexual arousal pathways independently of peripheral vascular mechanisms.

### Step 3: Oxytocin & Dopamine Release

Melanocortin receptor activation stimulates release of oxytocin (bonding, arousal) and dopamine (desire, reward) in brain circuits that mediate the neurological components of sexual function.

### Step 4: Central-to-Peripheral Integration

CNS activation cascades through autonomic pathways to produce integrated sexual response, combining enhanced desire and psychological arousal with downstream physiological responses.

## Researched Benefits

### Central Mechanism of Action

PT-141 works through brain melanocortin receptors rather than peripheral blood vessels, addressing the neurological and psychological components of sexual function. This makes it effective in cases where vascular-targeted treatments like PDE5 inhibitors are insufficient.

### FDA-Approved Efficacy

PT-141 (Vyleesi) received FDA approval in 2019 based on Phase III clinical trials enrolling over 1,200 patients. These trials demonstrated statistically significant improvements in sexual desire and reductions in distress, establishing a robust evidence base for its efficacy.

### PDE5 Non-Responder Option

Clinical research has demonstrated PT-141's efficacy in men who did not respond to sildenafil, affecting an estimated 30-40% of men with erectile dysfunction. Its distinct central mechanism offers an alternative pathway for individuals with non-vascular sexual dysfunction.

### Holistic Sexual Response

By acting on desire and arousal pathways in the brain, PT-141 enhances the complete sexual experience including psychological desire and motivation, rather than producing isolated physical responses in the absence of mental arousal.

## Dosage & Administration

| Parameter | Detail |
| --- | --- |
| Protocol | 1-2mg administered subcutaneously approximately 45 minutes before anticipated sexual activity |
| Route | Subcutaneous injection |
| Duration | As needed, not more than once every 24 hours, and no more than 8 doses per month |
| Cycle Notes | PT-141 is used on an as-needed basis rather than in continuous cycles. The FDA-approved dosing for women is 1.75mg per dose. Research protocols for men typically use 1-2mg per dose. Onset is approximately 45 minutes with effects lasting 6-12 hours. |
| Reconstitution | Reconstitute with bacteriostatic water. Using 10mg with 2mL yields 5000mcg/mL. Store reconstituted solution at 2-8°C and use within 28 days. |

> **Specialist note:** Cardiovascular assessment is required before initiating PT-141. The compound can cause transient blood pressure elevation and heart rate changes. Individuals with uncontrolled hypertension, cardiovascular disease, or those taking antihypertensive medications require careful evaluation. Nausea management may also need to be addressed.

## Compound Reference Data

| Property | Value |
| --- | --- |
| Format | Lyophilized Powder |
| Amount | 10mg per vial |
| Purity | >99.1% |
| Purity Method | HPLC (High-Performance Liquid Chromatography) |
| Sequence | Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH |
| Molecular Weight | 1025.18 g/mol |
| Storage | Store lyophilized powder at -20°C. Reconstituted solution at 2-8°C. Protect from light. |
| Appearance | White lyophilized powder |

## Medical Guidance

PT-141 can cause transient increases in blood pressure and decreases in heart rate, making cardiovascular screening mandatory before use. Individuals with uncontrolled hypertension, coronary artery disease, or those taking blood pressure medications require careful evaluation. PT-141 is contraindicated in uncontrolled hypertension. Nausea is reported in approximately 40% of users, and a specialist can recommend management strategies.

## Frequently Asked Questions

### How does PT-141 differ from Viagra or Cialis?

PT-141 works through a completely different mechanism. While Viagra (sildenafil) and Cialis (tadalafil) are PDE5 inhibitors that increase blood flow to genital tissue by acting on blood vessels, PT-141 acts in the brain by activating melanocortin receptors (MC3R/MC4R) in the hypothalamus. This central mechanism addresses desire and arousal at the neurological level rather than just the vascular level, making it effective in different types of sexual dysfunction.

### What medical guidance applies to PT-141?

PT-141 is a compound studied in clinical research that should only be used under qualified medical supervision. Cardiovascular screening is mandatory before initiating PT-141 due to its effects on blood pressure and heart rate. A specialist would assess cardiovascular status, current medications, and the underlying nature of sexual dysfunction to determine if PT-141 is appropriate.

### Is PT-141 FDA-approved?

PT-141 (bremelanotide) received FDA approval in 2019 under the brand name Vyleesi for treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. This approval was based on Phase III RECONNECT trials involving over 1,200 patients. While research-quality PT-141, the FDA-approved status means extensive clinical safety and efficacy data exists.

### What are the common side effects of PT-141?

The most commonly reported side effect is nausea, affecting approximately 40% of users in clinical trials. Transient blood pressure elevation, headache, flushing, and injection site reactions have also been reported. Most side effects are mild and self-limiting. A your specialist can recommend anti-nausea strategies and will monitor your blood pressure response to ensure cardiovascular safety.

### How quickly does PT-141 work?

PT-141 is typically administered 45 minutes before anticipated sexual activity, which aligns with its central nervous system processing time. Effects generally last 6-12 hours after administration. Unlike PDE5 inhibitors that require sexual stimulation to work, PT-141 enhances the underlying desire and arousal that precede physical response, working with the brain's natural sexual response circuitry.

## Related Compounds

- /compounds/bpc-157
- /compounds/cjc-1295-ipamorelin
- /compounds/selank